Blackstone Life Sciences’ $250 Million Investment in Anthos Therapeutics

Goodwin advised Anthos Therapeutics Inc. on the deal

Blackstone Life Sciences and Novartis launched Anthos Therapeutics Inc., a new biopharmaceutical company focused on advancing next generation targeted therapies for high-risk cardiovascular patients.

As part of this launch, Novartis has licensed to Anthos MAA868, an antibody directed at Factor XI and XIa, key components of the intrinsic coagulation pathway. A large unmet medical need exists for next-generation anti-thrombotic therapies in patients currently underserved by conventional anti-coagulant therapies. As a promising anti-thrombotic modulating genetically and pharmacologically validated components of the intrinsic pathway, MAA868 has the potential to prevent a variety of cardiovascular disorders with minimal or no bleeding risk within a new long-acting treatment paradigm, thus providing major advantages over the conventional standards of care.

Blackstone Life Sciences, a private investment platform with capabilities to invest across the lifecycle of companies and products across life sciences sectors, provided $250M for Anthos and will control the development of the products. Novartis will retain a minority equity interest in Anthos

Thrombotic disorders are estimated to account for one in four deaths and are the leading cause of mortality worldwide1. Thrombotic disorders can affect arteries or veins, manifesting as ischemic heart disease, ischemic stroke, peripheral artery disease, venous thromboembolism, and many debilitating orphan diseases. Atrial fibrillation, the most common type of heart arrhythmia, is a major risk factor for ischemic stroke and systemic arterial thromboembolism.

Goodwin advised Anthos on the deal with a team including Richard Hoffman (Picture), Noelle Dubiansky, Ed Amer, Priya Patel and Kimberley Maruncic.

Involved fees earner: Edward Amer – Goodwin Procter; Noelle Dubiansky – Goodwin Procter; Richard Hoffman – Goodwin Procter; Kimberley Maruncic – Goodwin Procter; Priya Patel – Goodwin Procter;

Law Firms: Goodwin Procter;

Clients: Anthos Therapeutics Inc;

Print Friendly, PDF & Email

Author: Ambrogio Visconti